Pulmonology Medical News about non-small cell lung cancer;Vorinostat;carboplatin;paclitaxel

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells
International Journal of Cancer, 09/08/09

Owonikoko TK et al. – Vorinostat interacts favorably with carboplatin and paclitaxel in NSCLC cells. This involves a vorinostat-mediated irreversible increase in DNA damage in the case of carboplatin and a reversible increase in microtubule stability in the case of paclitaxel.

Methods

Using the MTT assay 72 h after continuous drug exposure, growth inhibition of 4 NSCLC cell lines was assessed

Results

Vorinostat (1 microM) inhibited growth by 17%-41% in NSCLC
Vorinostat addition to carboplatin or paclitaxel led to significantly greater growth inhibition than chemotherapy alone in all 4 cell lines
When colony formation was measured after drug withdrawal, vorinostat significatly increased the effects of carboplatin, but not paclitaxel
The % colony formation was control 100%; 1 M vorinostat, 83% ± 10%; 5 M carboplatin, 41% ± 11%; carboplatin/vorinostat, 8% ± 4%; 2 nM paclitaxel, 53% ± 11%; paclitaxel/vorinostat, 46% ± 21%. In A549 and 128-88T, vorinostat potentiated carboplatin induction of gamma-H2AX (aDNA damage marker) and increased -tubulin acetylation (a marker for stabilized mictrotubules)

<< Previous
Emergency presentation and management of acute severe asthma in...

Next >>
Management of Patients with Allergic Rhinitis and Asthma:...